Rhabdomyosarcoma: Causes, Symptoms, Treatment and Prognosis — Overview, Diagnosis & Treatment Options | MyMedicPlus

Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children and adolescents, accounting for approximately 3-4% of childhood cancers and approximately 50% of pediatric soft tissue sarcomas. Despite its name, RMS arises from primitive mesenchymal cells that are committed to skeletal muscle lineage differentiation — not necessarily from differentiated skeletal muscle. Approximately 350 new cases are diagnosed annually in the United States. There are four main histological subtypes recognized by the 2020 WHO Classification: embryonal RMS (eRMS, approximately 60%), the most common and typically more favorable subtype seen in younger children; alveolar RMS (aRMS, approximately 20%), characterized by PAX3-FOXO1 or PAX7-FOXO1 oncogenic gene fusions and associated with worse prognosis; spindle cell/sclerosing RMS (approximately 10%); and pleomorphic RMS (primarily in adults). The primary anatomical sites are head and neck (approximately 40%), genitourinary tract (approximately 25%), and extremities (approximately 20%). COG IRS (Intergroup Rhabdomyosarcoma Study) grouping and TNM staging are used for risk stratification.

The dominant cause of alveolar RMS is the oncogenic chromosomal translocation t(2;13)(q35;q14) producing PAX3-FOXO1 fusion (approximately 55% of aRMS) or t(1;13)(p36;q14) producing PAX7-FOXO1 fusion (approximately 22% of aRMS). These fusion proteins function as aberrant transcription factors that block myogenic differentiation and drive proliferation. Embryonal RMS is typically characterized by chromosomal gains rather than specific translocations. Most cases arise sporadically without identifiable hereditary cause. Germline cancer predisposition syndromes are identified in approximately 7-8% of RMS patients: Li-Fraumeni syndrome (germline TP53 mutations) is the most strongly associated; neurofibromatosis type 1 (NF1, germline NF1 mutations) increases RMS risk approximately 20-fold; Beckwith-Wiedemann syndrome; Costello syndrome (germline HRAS gain-of-function mutations, associated with embryonal RMS particularly in the genitourinary tract); and DICER1 syndrome. Paternal age above 40 years has been associated with increased RMS risk in some studies.

Clinical presentation varies markedly by primary anatomical site, with symptoms reflecting local mass effect on adjacent structures. Head and neck (most common, approximately 40%): orbital RMS presents with unilateral proptosis (forward protrusion of the eye), ptosis, chemosis, and periorbital swelling — typically without pain; parameningeal RMS (arising in the nasopharynx, middle ear, mastoid, or paranasal sinuses) presents with nasal obstruction, blood-tinged nasal discharge, cranial nerve palsies (indicating skull base invasion), and otic symptoms; non-parameningeal head and neck RMS presents as visible or palpable facial mass. Genitourinary RMS: prostate or paratesticular RMS presents as firm scrotal or perineal mass; bladder/prostate RMS may cause hematuria, urinary frequency, or retention; vaginal RMS in infant girls presents as a polypoid mass protruding from the vagina (classic 'sarcoma botryoides' or grape-like appearance). Extremity RMS presents as a painless or mildly painful enlarging soft tissue mass that is often deep to the muscle fascia, commonly alveolar subtype with higher metastatic potential. Parameningeal tumors and alveolar extremity tumors are associated with higher rates of metastatic disease at diagnosis.

MRI of the primary tumor site with and without gadolinium contrast is the imaging modality of choice for defining tumor extent, invasion of adjacent structures, and neurovascular involvement. PET/CT with 18F-FDG is the standard for systemic staging (lymph node, bone, and distant metastasis detection) and has largely replaced bone scan plus CT in most centers. Bilateral bone marrow trephine biopsy is required for staging. Lumbar puncture for CSF cytology is essential for parameningeal RMS to detect CNS involvement. Core needle biopsy provides tissue for histological diagnosis with a comprehensive IHC panel (desmin+, MyoD1+, myogenin+), which confirms skeletal muscle lineage; FOXO1 FISH (for PAX3/7-FOXO1 fusions) is performed to distinguish aRMS from eRMS, as this distinction drives risk stratification and treatment intensity. COG IRS group (Group I: completely resected; II: microscopic residual; III: gross residual; IV: distant metastases) and COG risk stratification (low, intermediate, high) guide therapy selection. CSF cytology for parameningeal tumors.

RMS is treated with multimodality therapy: systemic chemotherapy, local control (surgery and/or radiotherapy), and continuation maintenance in some protocols — all guided by risk group assignment. Systemic chemotherapy is given to all RMS patients regardless of surgical resection completeness. The standard backbone for low- and intermediate-risk RMS is the VAC regimen (vincristine 1.5 mg/m², actinomycin D 0.045 mg/kg, cyclophosphamide 1.2 g/m²) every 3 weeks for 12-18 months. High-risk RMS (metastatic, alveolar) uses intensified regimens such as VDC/IE (vincristine-doxorubicin-cyclophosphamide alternating with ifosfamide-etoposide). Vinorelbine plus metronomic oral cyclophosphamide is studied as a maintenance strategy after standard therapy in European EpSSG protocols. Local control: surgery — wide local excision with negative margins when anatomically feasible — is the goal; however, many primary sites (orbit, parameningeal, bladder/prostate, vagina) are not amenable to primary resection without major functional deficit, so radiotherapy serves as the primary or adjuvant local control modality. Intensity-modulated radiotherapy (IMRT) and proton beam therapy (preferred at experienced centers for head/neck, parameningeal, and pelvic tumors) are used at 36-59.4 Gy depending on completeness of resection and group. Orbital RMS: radiation alone achieves excellent local control with globe preservation. Paratesticular RMS: orchiectomy with high ligation — retroperitoneal lymph node dissection or radiation based on age and nodal staging.

No preventive strategies exist for sporadic RMS, which arises from de novo oncogenic chromosomal translocations or somatic mutations without identifiable environmental triggers. For children with known hereditary cancer predisposition syndromes — particularly Li-Fraumeni syndrome, Costello syndrome, Beckwith-Wiedemann syndrome, and NF1 — structured surveillance programs including annual whole-body MRI (Toronto protocol for Li-Fraumeni) can detect early soft tissue malignancies including RMS at a potentially curable stage before symptomatic presentation. Genetic counseling is recommended for all pediatric patients with RMS, particularly those diagnosed at a young age, those with alveolar histology, those with a family history of multiple cancers, or those with associated developmental anomalies suggesting a hereditary syndrome. Avoiding known carcinogens during pregnancy (although no specific environmental exposures have been proven to cause RMS) is general health advice.

Parents and pediatricians should promptly investigate any rapidly enlarging soft tissue mass in a child — particularly if it is deep to the muscle fascia, firm, and larger than 3-5 cm — by MRI evaluation and referral to a pediatric oncologist. In a toddler girl, any grape-like polypoid mass protruding from the vagina must be evaluated urgently for sarcoma botryoides (vaginal embryonal RMS) and should not be treated empirically as a polyp or infection. Unilateral proptosis (forward protrusion of one eye) developing over days to weeks in a young child requires urgent ophthalmologic and oncology evaluation to exclude orbital RMS. A firm, painless paratesticular or scrotal mass in a boy under 10 years requires urgent ultrasound evaluation and urology referral. Any young child with cranial nerve palsy, unilateral nasal obstruction, or blood-tinged nasal discharge not explained by recurrent infection requires MRI evaluation of the sinonasal and skull base region. Families of children with Li-Fraumeni, NF1, Beckwith-Wiedemann, or other cancer predisposition syndromes should enroll in established cancer surveillance programs.

Low-risk embryonal RMS (localized, Group I/II): 5-year OS exceeds 90%. Intermediate-risk (most localized and regionally spread): approximately 65-80%. High-risk metastatic alveolar RMS: 5-year OS approximately 20-30%, representing the major unmet need in RMS. FOXO1-fusion positive tumors have worst prognosis. New targeted therapies and immunotherapy are under active investigation in COG and EpSSG trials. The prognosis for Rhabdomyosarcoma: Causes, Symptoms, Treatment and Prognosis varies depending on the severity of the condition at diagnosis, the patient's overall health, and how promptly treatment is initiated. With early diagnosis and appropriate management, many patients with Rhabdomyosarcoma: Causes, Symptoms, Treatment and Prognosis achieve good outcomes and can maintain quality of life. Regular follow-up with healthcare providers is essential to monitor progress, adjust treatment as needed, and detect any complications early. Adherence to prescribed treatments and lifestyle modifications significantly improves long-term prognosis.